Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines ANTIPLATELET THERAPY IN PATIENTS WITH CHRONIC KIDNEY DISEASE.

Slides:

Advertisements

Similar presentations

August 30, 2009 at CET. Ticagrelor compared with clopidogrel in patients with acute coronary syndromes – the PLATO trial.

Advertisements

Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines PERIOPERATIVE MANAGEMENT OF ANTIPLATELET THERAPY Working Group:

Leadership. Knowledge. Community. Antiplatelet Therapy for the Primary Prevention of Vascular Events Working Group: Alan D. Bell, MD, CCFP and James D.

RECOMMENDATIONS Canadian Cardiovascular Society Anti Platelet Guideline 2010 Alan D. Bell, MD, CCFP; Raymond Cartier, MD; Wee Shian Chan, MD, FRCP; James.

Leadership. Knowledge. Community. Guideline Pearls Canadian Cardiovascular Society Antiplatelet Guidelines.

Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines INTERACTION BETWEEN CLOPIDROGEL AND PROTON PUMP INHIBITORS Working.

Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines MANAGEMENT OF ANTIPLATELET THERAPY IN ASSOCIATION WITH MINOR.

Leadership. Knowledge. Community. Introduction Canadian Cardiovascular Society Antiplatelet Guidelines.

Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines USE OF ANTIPLATELET THERAPY IN WOMEN WHO ARE PREGNANT OR BREASTFEEDING.

Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines COMBINATION WARFARIN + ASA THERAPY WHEN: TO USE, TO CONSIDER,

Canadian Diabetes Association Clinical Practice Guidelines Acute Coronary Syndromes and Diabetes Chapter 26 Jean-Claude Tardif, Phillipe L. L’Allier, David.

Canadian Cardiovascular Society Antiplatelet Guidelines

North of Tyne anti-platelet guidelines: use in primary care Jane S Skinner Consultant Community Cardiologist.

Khawar Kazmi. Thrombosis LipidsInflammation Thrombus Platelets and thrombin Quiescent Plaque Plaque rupture PATHOGENESIS ACUTE CORONARY SYNDROME.

Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines HEART FAILURE Working Group: Alan D. Bell, MD, CCFP; James D.

Leadership. Knowledge. Community. USE OF ANTIPLATELET THERAPY IN PATIENTS WITH DIABETES Working Group: Maria E. Wolfs, MD, FRCP; Rémi Rabasa-Lhoret, MD,

Giuseppe Biondi-Zoccai Division of Cardiology, University of Turin, Turin, Italy.

Luigi Oltrona Visconti Divisione di Cardiologia IRCCS Fondazione Policlinico S. Matteo Pavia Sindromi coronariche acute nei pazienti con fibrillazione.

Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery 2007 ACC/AHA and 2009 ESC GUIDELINES.

Leadership. Knowledge. Community. Antiplatelet Therapy for Secondary Prevention Beyond One Year Following ACS or PCI Working Group: Anil Gupta MD, FRCPC,

Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines Antiplatelet Therapy for Vascular Prevention in Patients with.

European guidelines on the management of stable coronary artery disease Key points & new position for Ivabradine and Trimetazidine ESC 2013 Montalescot.

ACTIVE Clopidogrel plus Aspirin versus Aspirin in Patients Unsuitable for Warfarin.

ACS and Thrombosis in the Emergency Setting

Antiplatelet Therapy in Renal Dysfunction Moderator E. Magnus Ohman, MD Professor of Medicine Director Program for Advanced Coronary Disease Duke University.

Jacob A. Udell, MD, MPH, Marc P. Bonaca, MD, MPH, Jean-Philippe Collet, MD, PhD, A. Michael Lincoff, MD, Dean J. Kereiakes, MD, Francesco Costa, MD, Cheol.

Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.

Aspirin Resistance: Significance, Detection and Clinical Management of This Real Phenomenon Webcast May 10 th, 2004 Sponsored by.

What’s New in Acute Coronary Syndromes? Claudia Bucci BScPhm, PharmD Clinical Coordinator, Cardiovascular Diseases Sunnybrook Health Sciences Centre 13.

Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.

ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)

Pocket Guide to Anticoagulation in AF & Dual Antiplatelet Therapy in ACS Rumi Jaumdally 2015 This brief presentation will summarise the recently published.

NSTE Acute Coronary Syndromes

Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.

6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.

The Primary and Secondary Prevention of Cardiovascular Disease Per Olav Vandvik, MD, PhD A. Michael Lincoff, MD Joel M. Gore, MD David Gutterman, MD, FCCP.

TRITON TIMI-38 STEMI cohort Primary End Point (CV death, MI and stroke at 15 months) Adapted from Montalescot et al. ESC Time (days)

TRITON TIMI-38 STEMI cohort Clopidogrel Under Fire: Is Prasugrel in Primary PCI or Recent MI Superior? Insights From TRITON-TIMI-38 Gilles Montalescot,

The SYMPHONY Trial Reference Reddan DN, et al. Renal function, concomitant medication use and outcomes following acute coronary syndromes. Nephrol Dial.

수요저널 우종신. ACC/AHA Guideline Focused Update 2011 Class I 1. After PCI, use of aspirin should be continued indefinitely. (Level of Evidence.

CHU TIMONE, Marseille, FR

_________________ Caitlin M. Gibson, PharmD, BCPS

Canadian Cardiovascular Society Antiplatelet Guidelines

Cardiology Division, Jeju National University Hospital, Jeju, KOREA

Disclosures Speaker’s bureau: Research support: Consulting: Equity

Anticoagulation after peripheral Vascular Intervention

Denise Sutter, PharmD, BCPS

Focused 2012 Update of the Canadian Cardiovascular Society Guidelines for the Use of Antiplatelet Therapy Jean-François Tanguay, MD, CSPQ, FRCPC, FACC,

Should We Preload STEMI Patients with Antiplatelet Therapy?

Short versus Long DAPT Studies – An Academic View

The Big Antiplatelet Debate Why I Prefer Prasugrel Over Ticagrelor

The ANTARCTIC investigators

Learning Objectives. Learning Objectives Variable Response to Clopidogrel.

Preventing Thrombotic Complications in ACS: State of the Art

The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines Alan D. Bell, MD, CCFP, André Roussin, MD, FRCPC,

Introduction Antiplatelet Agents ADP Receptor Antagonists.

ATLANTIC Trial design: Participants with STEMI being transported for primary PCI were randomized in the ambulance to ticagrelor 180 mg (n = 909) vs. placebo.

Antiplatelet Therapy and Secondary Prevention

NOACS: Emerging data in ACS/IHD

ANTARCTIC Trial design: Patients with acute coronary syndrome undergoing stenting were randomized to tailored antiplatelet therapy (n = 435) versus conventional.

Would you recommend extending DAPT >1 year post-MI?

Focused 2012 Update of the Canadian Cardiovascular Society Guidelines for the Use of Antiplatelet Therapy Jean-François Tanguay, MD, CSPQ, FRCPC, FACC,

What oral antiplatelet therapy would you choose?

Presents to PCI-capable hospital and undergoes

Cardiology Fellow X Factor: An ACS Case of Therapeutic Challenges

Comparison of outcomes in patients with versus patients without diabetes; primary outcome event rate (CV death, non-fatal MI and non-fatal CVA) as a percentage.

Ticagrelor versus prasugrel; risk ratio with 95% CIs for the primary composite end point, primary composite end point in those undergoing PCI, myocardial.

Prasugrel and ticagrelor versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial.

Clinical Case Gilles Montalescot

Proposed future revascularisation strategy in patients with ESRD based on our current results and previous guideline recommendations. Proposed future revascularisation.

Presentation transcript:

Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines ANTIPLATELET THERAPY IN PATIENTS WITH CHRONIC KIDNEY DISEASE Working Group: Neesh Pannu, MD, SM, FRCP; Alan D. Bell, MD, CCFP

Interpret the Canadian Cardiovascular Society Guideline recommendations regarding the use antiplatelet therapy in patients with chronic kidney disease. Appropriately use antiplatelet therapy for primary and secondary prevention in patients with CKD. Evaluate the evidence supporting the use of antiplatelet therapy in patients with CKD. Objectives © TIGC

A 60 year hypertensive lady with long standing T2 diabetes is now on insulin. Her medications include glucophage, insulin, ramipril, amlodipine, HCT and pravastatin. She reports no vascular history but the physical exam reveals a carotid bruit. Her lab work has recently deteriorated, resulting in a Creat clear of 25 ml/min. The ECG is compatible with an old inferior infarctus. Case © TIGC

Antiplatelet management What antiplatelet therapy, if any, would you suggest? A. No antiplatelet therapy B. ASA 80 mg C. Clopidogrel 75 mg D. ASA 80 mg + Clopidogrel 75 mg © TIGC

Levey AS et al. Ann Intern Med 2003; 139: Chronic kidney disease National Kidney Foundation practice guidelines © TIGC

Fox CS et al. Circulation 2010; 121: Mortality according to CKD Stage STEMI and NSTEMI © TIGC

Angiolillo DJ et al. JACC 2010; 55: Platelet response to ASA + Clopidogrel according to CKD (306 diabetic patients with CAD) © TIGC

Fox CS et al. Circulation 2010; 121: Bleeding according to CKD stage STEMI and NSTEMI © TIGC

Primary prevention Antiplatelet therapy in haemodialysis ATC. BMJ 2002; 324: OR 41% © TIGC

10 ® Antiplatelet therapy Patients with chronic kidney disease 1.ASA mg daily may be considered for primary prevention of ischemic vascular events in patients with ESRD and a low risk of bleeding (Class IIb, Level C).

11 ®

Secondary prevention: ESRD after an acute MI Berger AK et al. JACC 2003; 42: ESDR © TIGC

Ezekowitz J et al. JACC 2004; 44: nonusernonuser Secondary prevention: Renal insufficiency, heart failure and CAD useruser nonusernonuser © TIGC

14 ® Antiplatelet therapy Patients with chronic kidney disease 1.Antiplatelet therapy should be considered for secondary prevention in patients with CKD and manifest vascular disease for which its benefits are established (Class IIa, Level C).

15 ®

Back to our case A 60 year hypertensive lady with long standing T2 diabetes is now on insulin. Her medications include glucophage, insulin, ramipril, amlodipine, HCT and pravastatin. She reports no vascular history but the physical exam reveals a carotid bruit. Her lab work has recently deteriorated, resulting in a Creat clear of 25 ml/min. The ECG is compatible with an old inferior infarctus. © TIGC

Antiplatelet management What antiplatelet therapy, if any, would you suggest ? A. No antiplatelet therapy B. ASA 80 mg C. Clopidogrel 75 mg D. ASA 80 mg + Clopidogrel 75 mg © TIGC

“What if” ACS Same patient comes back. She was recently hospitalized for a ACS and underwent a coronary angioplasty along with two stents deployed. How would that change your choice of antiplatelet therapy? © TIGC

Clopidogrel in CURE and CREDO Less effective if clearance below 60 ml/min ? Montalescot G et al. Circulation 2010; 122: © TIGC

Prasugrel in TRITON- TIMI 38: Primary end point

Prasugrel versus clopidogrel in TRITON- TIMI 38 Definite or probable stent thrombosis

Prasugrel (TRITON-TIMI 38) et Ticagrelor (PLATO) Primary outcome according to Creatinine clearance Montalescot G et al. Circulation 2010; 122: © TIGC

James S et al. Circulation 2010; 122: Ticagrelor (PLATO) and non-CABG TIMI major bleeding according to CKD status © TIGC

Ticagrelor (PLATO) and PLATO defined major bleeding according to CKD status James S et al. Circulation 2010; 122: © TIGC

Ticagrelor (PLATO) and PLATO defined major bleeding according to creatinine clearance James S et al. Circulation 2010; 122: © TIGC

Ticagrelor (PLATO) and Non-CABG-related TIMI major bleeding According to creatinine clearance over or under 60 ml/min James S et al. Circulation 2010; 122: © TIGC

Guidelines on myocardial revascularization European Society of Cardiology (ESC) Antiplatelet therapy in CKD Wijns W et al. EHJ 2010; 31: © TIGC

28 ® Antiplatelet therapy Patients with chronic kidney disease 2.Antiplatelet therapy should be considered for secondary prevention in patients with CKD and manifest vascular disease for which its benefits are established (Class IIa, Level C).

© TIGC